NeOnc books January FDA session to test faster route for nasal brain cancer drug
Nasdaq-listed NeOnc will ask US regulators in early 2027 whether intranasal NEO100 can be approved on an accelerated basis, with Phase 3 trial design also up for discussion.
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
NeOnc Technologies (Nasdaq: NTHI) has secured a formal slot with the US Food and Drug Administration in early January 2027 to discuss whether its intranasal brain cancer candidate, NEO100, could reach the market through accelerated approval. The company announced the meeting on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Approvals & launchesAll →
Approvals & launches
FDA approves Novartis' Cosentyx 150 mg for polymyalgia rheumatica
17 Nov 2026 · Novartis Pharma AG · Company news
Approvals & launches
FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
16 Nov 2026 · Roche · Company news
Approvals & launches
FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer
16 Nov 2026 · F. Hoffmann-La Roche Ltd · Company news
Approvals & launches
Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval
16 Nov 2026 · Larimar Therapeutics, Inc. LRMR · Company news
Approvals & launches
FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children
16 Nov 2026 · Essential Pharma · Company news